You are here: Industry Insights > Solid Biosciences

News List

Forge Biologics to provide CDMO support for Solid Biosciences' preclinical gene therapy CPhIonline
October 10, 2021
By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline
Solid Biosciences to Present at Upcoming Scientific Conferences firstwordpharma
May 26, 2021
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences
Gene therapy biotech shares sink on inconclusive trial results pharmaphorum
February 14, 2019
Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results in early clinical trials.
Solid Biosciences Discloses DMD Trial Setback Amid $125M IPO Push biospace
January 29, 2018
Solid Biosciences' failure to disclose some negative issues related to its work on a treatment for Duchenne muscular dystrophy (DMD) not only complicated its upcoming initial public offering (IPO), but is casting some shade on DMD research in general.